EP0584250A4 - - Google Patents

Info

Publication number
EP0584250A4
EP0584250A4 EP19920912707 EP92912707A EP0584250A4 EP 0584250 A4 EP0584250 A4 EP 0584250A4 EP 19920912707 EP19920912707 EP 19920912707 EP 92912707 A EP92912707 A EP 92912707A EP 0584250 A4 EP0584250 A4 EP 0584250A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920912707
Other versions
EP0584250A1 (en
Inventor
Pancras Chor Bun Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of EP0584250A1 publication Critical patent/EP0584250A1/en
Publication of EP0584250A4 publication Critical patent/EP0584250A4/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP92912707A 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers Withdrawn EP0584250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15
US700740 1991-05-15

Publications (2)

Publication Number Publication Date
EP0584250A1 EP0584250A1 (en) 1994-03-02
EP0584250A4 true EP0584250A4 (ja) 1994-03-30

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912707A Withdrawn EP0584250A1 (en) 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers

Country Status (11)

Country Link
EP (1) EP0584250A1 (ja)
JP (1) JP2930252B2 (ja)
AU (1) AU664375B2 (ja)
CA (1) CA2103276A1 (ja)
CZ (1) CZ281570B6 (ja)
IE (1) IE921534A1 (ja)
IL (1) IL101858A (ja)
MX (1) MX9202243A (ja)
NZ (1) NZ242724A (ja)
WO (1) WO1992020342A1 (ja)
ZA (1) ZA923557B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
JPH11500140A (ja) 1995-03-16 1999-01-06 ファイザー・インコーポレーテッド アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
SG142116A1 (en) 1998-07-10 2008-05-28 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR101194453B1 (ko) 2003-01-31 2012-10-24 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411766A1 (en) * 1989-07-03 1991-02-06 Merck & Co. Inc. Substituted quinazolinones as angiotensin II antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
AU656551B2 (en) * 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411766A1 (en) * 1989-07-03 1991-02-06 Merck & Co. Inc. Substituted quinazolinones as angiotensin II antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIU A.T. ET AL: "Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent", J. PHARMACOL. EXP. THER. (USA), 1990, VOL. 252, NO. 2, PAGE(S) 711-718, *
See also references of WO9220342A1 *

Also Published As

Publication number Publication date
ZA923557B (en) 1993-11-15
CZ235193A3 (en) 1994-03-16
NZ242724A (en) 1994-09-27
EP0584250A1 (en) 1994-03-02
JPH06508128A (ja) 1994-09-14
AU2026992A (en) 1992-12-30
IL101858A0 (en) 1992-12-30
CZ281570B6 (cs) 1996-11-13
WO1992020342A1 (en) 1992-11-26
CA2103276A1 (en) 1992-11-16
IE921534A1 (en) 1992-11-18
JP2930252B2 (ja) 1999-08-03
AU664375B2 (en) 1995-11-16
IL101858A (en) 1996-08-04
MX9202243A (es) 1992-11-01

Similar Documents

Publication Publication Date Title
DE9103238U1 (ja)
DE9103004U1 (ja)
DE9102092U1 (ja)
DE9102748U1 (ja)
DE9100936U1 (ja)
DE9102841U1 (ja)
DE9100476U1 (ja)
DE9102824U1 (ja)
DE9102314U1 (ja)
DE9102761U1 (ja)
DE9102355U1 (ja)
DE9101813U1 (ja)
DE9102335U1 (ja)
DE9102347U1 (ja)
DE9102333U1 (ja)
DE9100980U1 (ja)
DE9102098U1 (ja)
DE9102845U1 (ja)
DE9100251U1 (ja)
DE9100029U1 (ja)
DE9102878U1 (ja)
DE9101965U1 (ja)
DE9102063U1 (ja)
DE9101098U1 (ja)
DE9102275U1 (ja)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940208

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19981126

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RTI1 Title (correction)

Free format text: COMPOSITION OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010301